Welcome to our dedicated page for Sensei Biotherapeutics news (Ticker: SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics stock.
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) is a clinical stage biotechnology company in immuno-oncology, and the news flow around SNSE reflects its focus on cancer drug development, clinical data, and corporate strategy. The company regularly issues press releases on quarterly financial results, clinical trial milestones, capital markets actions, and strategic decisions, which are then furnished to the SEC on Form 8-K.
Recent news has centered on solnerstotug, Sensei’s lead product candidate. The company has released updates from a multi-center Phase 1/2 trial evaluating solnerstotug, a conditionally active antibody targeting the VISTA checkpoint, as monotherapy and in combination with Libtayo® (cemiplimab) in patients with advanced solid tumors. These announcements have highlighted emerging clinical signals in PD-(L)1 resistant “hot” tumors, durability of progression-free survival, safety and tolerability data, and presentations at major scientific meetings such as the ESMO Congress.
Investors following SNSE news also see corporate and financial updates, including quarterly earnings releases, commentary on research and development and general and administrative expenses, and disclosures about cash, cash equivalents, and marketable securities. Sensei has additionally reported participation in investor and scientific conferences, such as healthcare and oncology events where company representatives discuss its tumor microenvironment–focused approach.
A key development in the company’s news stream is the strategic review announced on October 30, 2025, when Sensei’s Board decided to discontinue development of solnerstotug and explore strategic alternatives that may include asset sales, licensing, collaborations, a sale of the company, a business combination, a merger, or an orderly wind-down of operations. Subsequent news has described workforce reductions and the company’s intention to retain a smaller team to manage this process and maintain regulatory and financial reporting compliance.
This news page allows readers to track these evolving themes: clinical data releases, financial results, Nasdaq listing and reverse stock split actions, and updates on the strategic alternatives process, all of which shape the ongoing story of SNSE.
Sensei Biotherapeutics (Nasdaq: SNSE) has announced its participation in the SITC 37th Annual Meeting in Boston from November 8-12, 2022. The company will present two posters highlighting their advancements in immuno-oncology. The first presentation will focus on novel T-cell receptors related to the VSIG4 macrophage receptor, while the second will discuss SNS-101, an antibody that enhances anti-PD-1 sensitivity in tumors. These advancements underscore Sensei's commitment to developing innovative cancer therapeutics using their TMAb and ImmunoPhage platforms.
Sensei Biotherapeutics (NASDAQ: SNSE) presented promising data on SNS-101, a monoclonal antibody targeting the immune checkpoint VISTA, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference. Preclinical results indicate SNS-101 enhances anti-tumor effects when combined with anti-PD-1 antibodies, achieving five complete responses in a resistant tumor model. The antibody also exhibits a favorable pharmacokinetic profile, reducing the risk of cytokine release syndrome compared to traditional VISTA antibodies. This data may support SNS-101's potential for broad oncological applications.
Sensei Biotherapeutics (Nasdaq: SNSE) announced it will present new preclinical data on SNS-101, a monoclonal antibody targeting the immune checkpoint VISTA, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference in New York from September 28 to October 1, 2022. The poster presentation is scheduled for September 30, highlighting SNS-101's favorable pharmacokinetic properties and its potential to enhance anti-PD-1 responses. This aligns with Sensei's mission of developing next-generation cancer therapeutics.
Sensei Biotherapeutics (NASDAQ: SNSE) announced preliminary preclinical data for SNS-101, an antibody targeting the VISTA immune checkpoint. Results indicate that SNS-101 effectively overcomes pharmacokinetic challenges and enhances anti-tumor effects when combined with anti-PD-1 antibodies. Additionally, SNS-101 shows a favorable pharmacokinetic profile, with a median half-life of approximately three weeks. Ongoing IND-enabling studies aim to evaluate SNS-101's potential for treatment in solid cancers, with an IND filing planned for the first half of 2023.
Sensei Biotherapeutics (NASDAQ: SNSE) announced its participation in two key investor conferences in September 2022, aimed at exploring the latest in immuno-oncology developments.
The conferences are:
- Citi’s 17th Annual Biopharma Conference (September 7-8, Boston, MA)
- Wells Fargo’s 2022 Healthcare Conference (September 7-9, Boston, MA)
Interested portfolio managers and analysts can arrange meetings with company management through their respective representatives.
Sensei Biotherapeutics (NASDAQ: SNSE) announced progress in its clinical programs, including pre-IND feedback from the FDA for SNS-101, an anti-VISTA antibody, expected to file an IND in the first half of 2023. The company will present new pharmacokinetic data in non-human primates in Q3 2022. The strong financial position, with cash equivalents of $123.7 million, supports operations through Q1 2025. Research and development expenses increased to $6.4 million due to higher headcount and inflation. The net loss was reported at $10.5 million for Q2 2022.
On June 1, 2022, Sensei Biotherapeutics (NASDAQ: SNSE) announced the appointment of Patrick Gallagher as Chief Business Officer. Gallagher, an experienced biotech executive, will leverage his nearly 20 years in the pharmaceutical and biotech sectors to enhance Sensei's strategic initiatives. His past roles include significant contributions to various reputable companies and investment banking firms. This leadership change is expected to strengthen the company's position during critical phases of program advancements.
Sensei Biotherapeutics, a leader in immunotherapy, announced that CEO John Celebi will present at the Jefferies Healthcare Conference on June 8, 2022, at 3:00 p.m. ET, both in-person and virtually in New York, NY. Investors can access a live webcast of the presentation on the company's website, with a replay available for 90 days afterward. Sensei focuses on developing innovative cancer therapies, utilizing its TMAb™ and ImmunoPhage™ platforms. Their lead therapeutic candidate, SNS-101, targets the VISTA checkpoint to enhance T cell activity in the tumor microenvironment.
Sensei Biotherapeutics (SNSE) reported Q1 2022 financial results, highlighting a net loss of $12.4 million, up from $8.0 million in Q1 2021. The company's cash reserves stood at $136.2 million, sufficient to fund operations through Q1 2025. Progress on the TMAb™ platform includes promising preclinical data for SNS-101, an anti-VISTA antibody targeting solid tumors, which showed selective binding in low pH environments. The firm also anticipates submitting an IND for SNS-101 in the first half of 2023 following successful GMP manufacturing initiation.
Sensei Biotherapeutics (NASDAQ: SNSE) announced significant advancements in its pipeline with the initiation of new therapeutic programs, including SNS-101, an anti-VISTA antibody. The company reported a strong cash position of $147.6 million as of December 31, 2021, providing a runway into the first half of 2024. Additionally, the management team was strengthened with key appointments. SNS-101 shows promise against the VISTA immune checkpoint, vital for overcoming challenges in cancer treatment.